Cargando…

HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects

Little is known about the humoral immune response against DNA prime-recombinant adenovirus 5 (rAd5) boost HIV vaccine among HIV-infected patients on long-term suppressive antiretroviral therapy (ART). Previous studies emphasized cellular immune responses; however, current research suggests both cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gach, Johannes S., Gorlani, Andrea, Dotsey, Emmanuel Y., Becerra, Juan C., Anderson, Chase T. M., Berzins, Baiba, Felgner, Philip L., Forthal, Donald N., Deeks, Steven G., Wilkin, Timothy J., Casazza, Joseph P., Koup, Richard A., Katlama, Christine, Autran, Brigitte, Murphy, Robert L., Achenbach, Chad J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4976892/ https://www.ncbi.nlm.nih.gov/pubmed/27500639 http://dx.doi.org/10.1371/journal.pone.0160341

Ejemplares similares

A High Throughput Protein Microarray Approach to Classify HIV Monoclonal Antibodies and Variant Antigens
por: Dotsey, Emmanuel Y., et al.
Publicado: (2015)

HIV-1 Specific Antibody Titers and Neutralization among Chronically Infected Patients on Long-Term Suppressive Antiretroviral Therapy (ART): A Cross-Sectional Study
por: Gach, Johannes S., et al.
Publicado: (2014)

High Intensity Walking Reduces Frailty and Improves Physical Function Among Older Adults Living With HIV
por: Danilovich, Margaret, et al.
Publicado: (2020)

P18-06. Increased HIV-specific immunity in HIV-infected individuals vaccinated with a DNA prime, rAd5 boost regimen
por: Casazza, JP, et al.
Publicado: (2009)

Human immunodeficiency virus type-1 (HIV-1) evades antibody-dependent phagocytosis
por: Gach, Johannes S., et al.
Publicado: (2017)

A novel mechanism of HIV transcytosis and infection
por: Gupta, S, et al.
Publicado: (2012)

No difference in anti-spike antibody and surrogate viral neutralization following SARS-CoV-2 booster vaccination in persons with HIV compared to controls (CO-HIV Study)
por: Kling, Kendall D., et al.
Publicado: (2023)

High-risk human papilloma virus and cervical abnormalities in HIV-infected women with normal cervical cytology
por: Musa, Jonah, et al.
Publicado: (2014)

Similar changes in neuropsychological functioning in english and spanish speaking HIV patients
por: Akpa, Onoja, et al.
Publicado: (2018)

Potency of an HIV-SAM™ vaccine in a heterologous prime-boost vaccination regimen
por: Banerjee, K, et al.
Publicado: (2012)

Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV
por: Chapman, Ros, et al.
Publicado: (2021)

Antibody-mediated inhibition of HIV-1 elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults
por: Joachim, A, et al.
Publicado: (2012)

Adenovirus antibodies assist HIV
por: Maxmen, Amy
Publicado: (2008)

Enhanced immune response against HIV-1 induced by a heterologous DNA prime-adenovirus boost vaccination using mannosylated polyethyleneimine as DNA vaccine adjuvant
por: Li, Man, et al.
Publicado: (2013)

Recent Insights into the HIV/AIDS Pandemic
por: Becerra, Juan C., et al.
Publicado: (2016)

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials
por: Brown, Scott A., et al.
Publicado: (2010)

Comparative Immunogenicity of HIV-1 Clade C Envelope Proteins for Prime/Boost Studies
por: Smith, Douglas H., et al.
Publicado: (2010)

Frequent and Durable Anti-HIV Envelope VIV2 IgG Responses Induced by HIV-1 DNA Priming and HIV-MVA Boosting in Healthy Tanzanian Volunteers
por: Joachim, Agricola, et al.
Publicado: (2020)

Modified Adenovirus Prime-Protein Boost Clade C HIV Vaccine Strategy Results in Reduced Viral DNA in Blood and Tissues Following Tier 2 SHIV Challenge
por: Malherbe, Delphine C., et al.
Publicado: (2021)

Perspectives for immunotherapy: which applications might achieve an HIV functional cure?
por: Vieillard, Vincent, et al.
Publicado: (2016)

Potent Functional Antibody Responses Elicited by HIV-I DNA Priming and Boosting with Heterologous HIV-1 Recombinant MVA in Healthy Tanzanian Adults
por: Joachim, Agricola, et al.
Publicado: (2015)

Adjuvant-dependent cytokine profiles in the context of a DNA prime-protein boost HIV-1 vaccine
por: Buglione-Corbett, R, et al.
Publicado: (2012)

HIV Envelope Trimer Specific Immune Response Is Influenced by Different Adjuvant Formulations and Heterologous Prime-Boost
por: Apostólico, Juliana de Souza, et al.
Publicado: (2016)

DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial
por: Rouphael, Nadine G., et al.
Publicado: (2019)

Priming with a “simplified regimen” of HIV-1 DNA vaccine is as good as a “standard regimen” when boosted with heterologous HIV-1 MVA vaccine
por: Munseri, P, et al.
Publicado: (2012)

Alphavirus Replicon DNA Expressing HIV Antigens Is an Excellent Prime for Boosting with Recombinant Modified Vaccinia Ankara (MVA) or with HIV gp140 Protein Antigen
por: Knudsen, Maria L., et al.
Publicado: (2015)

Towards an HIV cure
por: Deeks, Steven
Publicado: (2014)

Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients
por: Butterfield, Lisa H, et al.
Publicado: (2014)

HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and are Commonly Detected in Plasma from HIV-infected Humans
por: Williams, Katherine L., et al.
Publicado: (2015)

Reconsidering Early HIV Treatment and Supervised Treatment Interruptions
por: Koup, Richard A
Publicado: (2004)

Coronary Microvascular Dysfunction in HIV: A Review
por: Rethy, Leah, et al.
Publicado: (2019)

Safety and Immunogenicity of DNA and MVA HIV-1 Subtype C Vaccine Prime-Boost Regimens: A Phase I Randomised Trial in HIV-Uninfected Indian Volunteers
por: Mehendale, Sanjay, et al.
Publicado: (2013)

A Novel Prime and Boost Regimen of HIV Virus-Like Particles with TLR4 Adjuvant MPLA Induces Th1 Oriented Immune Responses against HIV
por: Poteet, Ethan, et al.
Publicado: (2015)

Potent HIV-1-Specific CD8 T Cell Responses Induced in Mice after Priming with a Multiepitopic DNA-TMEP and Boosting with the HIV Vaccine MVA-B
por: Perdiguero, Beatriz, et al.
Publicado: (2018)

Emerging role of integrase inhibitors in the management of treatment-experienced patients with HIV infection
por: Katlama, Christine, et al.
Publicado: (2009)

Impact of Anti PD-1 Immunotherapy on HIV Reservoir and Anti-Viral Immune Responses in People Living with HIV and Cancer
por: Baron, Marine, et al.
Publicado: (2022)

Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles
por: Bridge, Simon H, et al.
Publicado: (2011)

Accelerated heterologous prime-boost adenovirus vector-based SIV vaccine in neonatal rhesus monkeys
por: Liu, J, et al.
Publicado: (2012)

Induction of HIV-1 Gag-specific memory T cells in Chacma baboons by MVA prime and VLP boost vaccine regimen
por: Singh, V, et al.
Publicado: (2012)

Increased surface expression of HIV-1 envelope is associated with improved antibody response in vaccinia prime/protein boost immunization
por: Hogan, Michael J., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_68511schotbq5083lu3l2bqkc2